Start typing to retrieve search suggestions. When suggestions are available use up and down arrows to review and ENTER to select. Continue typing to refine.
Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Denbrayce 120 mg Solution for injection {equilateral_black_triangle}

Active Ingredient:
denosumab
Company:  
Mabxience Research S.L See contact details
ATC code: 
M05BX04
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Denbrayce 120 mg - Patient reminder card

This reminder card contains important safety information that the patient needs to be aware of before and during treatment with denosumab 120 mg injections for cancer-related conditions or giant cell tumour of bone (GCTB).

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Mabxience Research S.L
Company image
Address
Telephone
+ 34 917 71 15 00
Medical Information Direct Line
+34 675 531 773
Medical Information e-mail
[email protected]
WWW
www.mabxience.com